Coagulation problems in human pregnancy.
Coagulation problems in pregnancy are primarily associated with overactivity of the intrinsic clotting system. This accounts for the increased incidence of thrombo-embolism during pregnancy. Where specific obstetric complications cause clotting problems the common underlying feature is usually placental pathology as in abruptio placentae, pre-eclampsia or hydatidiform mole. Abnormal activation of the clotting system is an early, and occasionally the first detectable feature of pre-eclampsia, but there is no evidence that this is a primary change. Therefore the role of anticoagulant treatment in the management of pre-eclampsia remains questionable. A new test for estimating factor VIII consumption is proving to be a sensitive index of early activation of the clotting system and can be used for the diagnosis of early pre-eclampsia.
D000037:Abruptio Placentae / Q000150:complications; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000209:etiology* / Q000503:physiopathology; D004619:Embolism, Amniotic Fluid / Q000150:complications; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000150:complications; D011225:Pre-Eclampsia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D013923:Thromboembolism / Q000188:drug therapy / Q000503:physiopathology; D014594:Uterine Neoplasms / Q000150:complications
D000925:Anticoagulants